ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in extensive stage small cell lung cancer
The study, led by Yale University, explore the combination with atezolizumab and radiation therapy.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with radiotherapy and an immune checkpoint inhibitor in patients with residual, progressive or recurrent extensive stage small cell lung cancer (ES-SCLC). The study is sponsored and conducted by Yale University.
The trial (NCT07113691), titled “Iadademstat and Radiation Therapy With Atezolizumab in Extensive Stage Small-cell Lung Cancer (ES-SCLC) Patients With Persistent, Recurrent or Progressive Disease After First Line Systemic Therapy”, is an open-label, non-randomized Phase Ib study that will evaluate the safety, tolerability, and efficacy of iadademstat combined with atezolizumab and stereotactic body radiation therapy (SBRT) followed by maintenance therapy with atezolizumab and iadademstat. The study will enroll patients with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy. Dr. Anne Chiang at Yale University is serving as Principal Investigator.
Dr. Carlos Buesa, Oryzon’s CEO, stated: “The initiation of this investigator-led study at Yale University represents an important milestone in our efforts to expand the clinical development of iadademstat in small cell lung cancer. Combining LSD1 inhibition with immunotherapy and radiotherapy is a compelling strategy, and we look forward to the insights this trial may provide into the potential role of iadademstat in addressing this aggressive disease with high unmet medical need.”
Dr. Chiang, Principal Investigator of the study, added: “Some SCLC patients have had long-term benefit with immunotherapy, and we hope to learn how to extend benefit to more people. Through this study, we aim to boost the immune response by adding radiation and iadademstat to immunotherapy in SCLC patients. The use of paired biopsies will help us understand key events that are occurring in the tumor and its microenvironment as well.”